giovanni cafio brystol myerssquibb email

du Pont de Nemours and Company.Ĭornelius has been non-executive chairman since May 2010. He also sits on the board of directors of E. He held a number of roles of increasing responsibility and was elected to the board of directors in March 2009. from the University of Rome prior to joining the pharmaceutical industry.Īndreotti joined Bristol-Myers Squibb in 1998 as vice president and general manager, Italy and European Oncology. He joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy. A trained physician, Caforio began his career in Medical Affairs at Abbott Laboratories. As a member of the company's Senior Management Team since 2011 and the company's board of directors since 2014, Caforio has been integral in shaping the company's successful transformation to a Diversified Specialty BioPharma company. As chief commercial officer and chief operating officer he led the transformation of the company's global commercial organization into one uniquely designed to be able to differentially invest in the most important opportunities. He helped build the company's leadership in immuno-oncology through his roles in U.S. Through ever-expanding roles, Caforio has made significant contributions to improving the company's strategic focus and operational performance. 'With Giovanni's appointment as CEO and Lamberto's appointment as chairman, we ensure the continuation of both the leadership and strategy that have made BMS successful.'Ĭaforio brings a broad range of experience to his role as CEO. 'This is an extraordinary company of talented people with incomparable passion and dedication to helping patients,' Cornelius said. I look forward to working with our very talented team of people at BMS to build on what we've accomplished, to deliver on the promise of our innovative portfolio and to continue to make a real difference for our patients.' 'Lamberto has led the successful transformation of BMS from a broad-based health care company to a Diversified Specialty BioPharma leader with his passion for our business, our people and, most importantly, our patients.

'I am honored to have the privilege to lead this great company,' Caforio said. From his start in a medical role to his experience as a general manager to his roles as chief commercial officer and chief operating officer, Giovanni has demonstrated a unique ability to work across the organization to bring innovative medicines to patients.' He has an unmatched breadth and depth of experience. 'I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance. 'I also want to express my excitement that Giovanni has been appointed to succeed me as CEO,' Andreotti said. As CEO of Bristol-Myers Squibb, I am grateful to have had his guidance as a mentor and a friend.' 'Through his leadership and strategic vision, Jim oversaw the successful transformation of our company. 'I want to thank Jim Cornelius for his many years at BMS,' Andreotti said. West, Jr., 72, will become the lead independent director on the company's board. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. Lamberto Andreotti, 64, will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3.Giovanni Caforio, M.D., 50, will become chief executive officer of the company.NEW YORK-( BUSINESS WIRE)- Bristol-Myers Squibb Company (NYSE:BMY) today announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders' Meeting on May 5.

Giovanni cafio brystol myerssquibb email